AstraZeneca PLC Block listing Interim Review (4365V)
01 Diciembre 2023 - 9:05AM
UK Regulatory
TIDMAZN
RNS Number : 4365V
AstraZeneca PLC
01 December 2023
1 December 2023 15:05 GMT
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed
electronically and provided to an ris.
(Note: Italicised terms have the same meaning as given in the
Listing Rules.)
Date : 1 December 2023
Name of applicant: ASTRAZENECA PLC
Name of scheme: ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE
OPTION PLAN; ASTRAZENECA
ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED
SHARE OPTION SCHEME
------------------------------------------------------------------
Period of return: From: 1 JUNE 2023 To: 30 NOVEMBER 2023
----------------------- ------------------------- ------------- ------------------------
Balance of unallotted securities under scheme(s)
from previous return: 4,476,382
------------------------------------------------------------------
Plus: The amount by which the block scheme(s) has
been increased since the date of the last
return (if any increase has been applied for): 0
------------------------------------------------------------------
Less: Number of securities issued/allotted under
scheme(s) during period (see LR3.5.7G): 56,248
------------------------------------------------------------------
Equals: Balance under scheme(s) not yet
issued/allotted at end of period: 4,420,134
------------------------------------------------------------------
Name of contact: Hannah Tattersall
Telephone number of contact: +44 (0)746 498 2582
--------------------
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and follow the
Company on Twitter @AstraZeneca .
Contacts
For details on how to contact the Investor Relations Team,
please click here . For Media contacts, click here .
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BLRFSSFEFEDSELE
(END) Dow Jones Newswires
December 01, 2023 10:05 ET (15:05 GMT)
Astrazeneca (LSE:0A4J)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Astrazeneca (LSE:0A4J)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024